Evidence map›Paper›PMID 40328984›Full record

ArticleNPJ digital medicine2025

Rapid development of a registry to accelerate COVID-19 vaccine clinical trials.

Neil F Abernethy, Kylie McCloskey, Meg Trahey, Laurie Rinn, Gail Broder, Michele Andrasik, Rebecca Laborde, Daniel McGhan, Scott Spendolini, Senthil Marimuthu and 3 more

Abstract read
In one paragraph

Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Building Trust and Engaging Communities for HIV Prevention Research Globally.AIDS education and prevention : official publication of the International Society for AIDS Education · 2026
    Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Neil F AbernethyBiomedical Informatics and Medical Education, University of Washington, Seattle, WA, USA.
Kylie McCloskeyHIV Vaccine Trials Network (HVTN), COVID-19 Prevention Network (CoVPN), Fred Hutchinson Cancer Center, Seattle, WA, USA.
Meg TraheyHIV Vaccine Trials Network (HVTN), COVID-19 Prevention Network (CoVPN), Fred Hutchinson Cancer Center, Seattle, WA, USA.
Laurie RinnHIV Vaccine Trials Network (HVTN), COVID-19 Prevention Network (CoVPN), Fred Hutchinson Cancer Center, Seattle, WA, USA.
Gail BroderHIV Vaccine Trials Network (HVTN), COVID-19 Prevention Network (CoVPN), Fred Hutchinson Cancer Center, Seattle, WA, USA.
Michele AndrasikHIV Vaccine Trials Network (HVTN), COVID-19 Prevention Network (CoVPN), Fred Hutchinson Cancer Center, Seattle, WA, USA.
Rebecca LabordeOracle Corporation, Austin, TX, USA.
Daniel McGhanOracle Corporation, Austin, TX, USA.
Scott SpendoliniOracle Corporation, Austin, TX, USA.
Senthil MarimuthuOracle Corporation, Austin, TX, USA.
Adam KanzmeierOracle Corporation, Austin, TX, USA.
Jayson HanesOracle Corporation, Austin, TX, USA.
James G KublinHIV Vaccine Trials Network (HVTN), COVID-19 Prevention Network (CoVPN), Fred Hutchinson Cancer Center, Seattle, WA, USA. jkublin@fredhutch.org.ORCID http://orcid.org/0000-0003-1279-3741

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068635U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1AI068614U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1AI068635
6 · The paper itself

Abstract

Response to the SARS-Cov-2 pandemic required the unprecedented, rapid activation of the COVID-19 Prevention Network (CoVPN) representing hundreds of sites conducting vaccine clinical trials. The CoVPN Volunteer Screening Registry (VSR) collected participant information, distributed qualified candidates across sites, and monitored enrollment progress. The system consisted of three web-based interfaces. The Volunteer Questionnaire flowed into a secure database. The Site Portal supported volunteer selection, analytics, and enrollment. The Administrative Portal enabled dynamic analytic reports by geography, clinical trial, and site, including volunteering rates over time. The VSR collected over 650,000 volunteers, serving a key role in the recruitment of diverse participants for multiple Phase 3 clinical trials. Over 47% of the 166,729 volunteers selected for screening represented prioritized groups. The success of the VSR demonstrates how digital tools can be rapidly yet safely integrated into an accelerated clinical trial setting. We summarize the development of the system and lessons learned for pandemic preparedness.

Identifiers

PMID40328984
PMCPMC12056171

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.